Safety of Masitinib Mesylate in Healthy Cats

Journal of Veterinary Internal Medicine

Volumn 25, Issue 2, 2011, Pages 297-302

  Daly, M ^a   Sheppard, S ^a   Cohen, N ^a   Nabity, M ^a   Moussy, A ^b   Hermine, O ^c   Wilson, H ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b AB Science   (France)

^c CNRS   (France)

Author keywords

Cat; Feline; Receptor tyrosine kinase inhibitor

Indexed keywords

MASITINIB; PROTEIN KINASE INHIBITOR; THIAZOLE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CAT; CAT DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; GERMFREE ANIMAL; MALE; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; CAT DISEASES; CATS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; MALE; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; SPECIFIC PATHOGEN-FREE ORGANISMS; THIAZOLES;

ANIMALIA; CANIS FAMILIARIS; FELIDAE;

EID: 79952353379     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.0687.x     Document Type: Article

References (23)

1. Letard S, Yang Y, Hanssens K, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 2008;16:1137-1145.
2. Pierotti MA, Negri T, Tamborini E, et al. Targeted therapies: The rare cancer paradigm. Mol Oncol 2010;4:19-37.
3. Humbert M, de Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009;64:1194-1201.
4. Daigle J, Moussy A, Mansfield CD, Hermine O. Masitinib for the treatment of canine atopic dermatitis: A pilot study. Vet Res Commun 2010;34:51-63.
5. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 2004;4:361-370.
6. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010) a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 2009;4(9):e7258. doi:DOI: 10.1371/journal.pone.0007258.
7. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1301-1309.
8. Bellamy F, Bader T, Moussy A, Hermine O. Pharmacokinetics of masitinib in cats. Vet Res Commun Dec 2009;33:831-837.
9. London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med. 2009;24:106-112.
10. Lachowicz JL, Post GS, Brodsky E. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. J Vet Intern Med 2005;19:860-864.
11. Isotani M, Tamura K, Yagihara H, et al. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Vet Immunol Immunopathol 2006;114:168-172. Epub September 5, 2006.
12. Isotani M, Yamada O, Lachowicz JL, et al. Mutation in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. Br J Haematol 2009;148:144-153.
13. Veterinary Co-operative Oncology Group. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats. V.10. Vet Comp Oncol 2004;2:194-213.
14. Sum S, Hensel P, Rios L, et al. Drug-induced minimal change nephropathy in a dog. J Vet Intern Med 2010;24:431-435.
15. Miliaras D, Karasavvidou F, Papanikolaou A, et al. KIT expression in fetal, normal adult, and neoplastic renal tissues. J Clin Pathol 2004;57:463-466.
16. Alpers C, Seifert R, Hudkins K, et al. PDGF-receptor localices to mesangial, parietal epithelial, and interstitial cells in human and primate kidneys. Kidney Int 1993;43:286-294.
17. Sato R, Soeta S, Syuto B, et al. Urinary excretion of N-acetyl-β-D-glucosaminidase and its isoenzymes in cats with urinary disease. J Vet Med Sci 2002;64:367-371.
18. Lapointe C, Bélanger MC, Dunn M, et al. N-acetyl-β-D-glucosaminidase index as an early biomarker for chronic kidney disease in cats with hyperthyroidism. J Vet Intern Med 2008;22:1103-1110.
19. Tebib J, Mariette X, Bourgeois P, et al. Masitinib in the treatment of active rheumatoid arthritis: Results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther 2009;11:R95 doi: DOI: 10.1186/ar2740.
20. Janas ML, Hodgkin P, Hibbs M, Tarlinton D. Genetic evidence for Lyn as a negative regulator of IL-4 signaling. J Immunol 1999;163:4192-4198.
21. Withrow S, Vail D. Soft tissue sarcomas. Withrow and MacEwen's Small Animal Clinical Oncology, 4th ed. Philadelphia, PA: Saunders; 2006:425-454.
22. Nieto A, Sanchez A, Martinez E, Rollan E. Immunohistochemical expression of p53, fibroblast growth factor-b, and transforming growth factor-α in feline vaccine-associated sarcomas. Vet Pathol (2003);40:651-658.
23. Katayama R, Huelsmeyer MK, Marr AK, et al. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 2004;54:25-33.